Chlorhexidine or Oral Cooling Decrease Chemotherapy-induced Mucositis (3/31/2008)
Researchers from Denmark have reported that chlorhexidine mouth washes or oral cooling decreases the incidence and severity of oral mucositis associated with 5 FU and leucovorin-based chemotherapy for gastrointestinal cancer. The details of this randomized study appeared in an early online publication in Cancer on February 15, 2008.

Kepivance® May Decrease Oral Mucositis Following High-Dose Chemotherapy (1/8/2007)
There were several clinical studies presented at the 2006 meeting of the American Society of Hematology in December which suggest that Kepivance (palifermin) is effective in decreasing the incidence, severity and duration of severe oral mucositis in patients with hematologic diseases receiving high-dose Alkeran® (melphalan) (200 mg/m2) or high-dose BEAM (carmustine, etoposide, cytarabine and melphalan) followed by autologous stem cell infusion.

Kepivance® Decreases Oral Mucositis in Patients with Metastatic Colorectal Cancer. (11/27/2006)
The results of a randomized multicenter trial demonstate that Kepivance (palifermin, keritinocyte growth factor) given before chemotherapy reduces the incidence of severe oral mucositis in patients receiving 5-FU/leucovorin for metastatic colorectal cancer.

Kepivance® Reduces Mucositis After Allogeneic Stem Cell Transplantation Without Impact on Acute GVHD (11/9/2006)
Researchers from the University of Minnesota and Michigan have reported that the administration of Kepivance (palifermin, keritinocyte growth factor) before and after allogeneic stem cell transplantation reduces the incidence and mean severity of mucositis in patients receiving a total body irradiation (TBI) conditioning regimen.

Daily Low Power Laser Therapy May Prevent Oral Mucositis in Stem Cell Transplant Patients (10/25/2006)
Researchers from Brazil have reported that low power laser therapy (LPLT) reduces the incidence of grade 2-4 oral mucositis by 60% following autologous or allogeneic stem cell transplantation.